A chemical modification that occurs in some RNA molecules as they carry genetic instructions from DNA to cells' protein-making machinery may offer protection against non-alcoholic fatty liver, a condition that results from a build-up of fat in the liver and can lead to advanced liver disease, according to a new study by UCLA researchers.
The study, conducted in mice, also suggests that this modification -- known as m6A, in which a methyl group attaches to an RNA chain -- may occur at a different rate in females than it does in males, potentially explaining why females tend to have higher fat content in the liver. The researchers found that without the m6A modification, differences in liver fat content between the sexes were reduced dramatically.
In addition, in a preclinical model, the investigators demonstrated that gene therapy can be used to enhance or add modifications to key RNAs to slow down or reduce the severity of liver disease.
Fatty liver can develop when liver fat content increases due to dietary or genetic factors, potentially leading to advanced liver scarring and disease, as seen in cirrhosis and other conditions. High liver fat content is also associated with increased risk of cardiovascular disease.
In recent years, scientists have identified hundreds of chemical modifications like m6A that can occur in RNA molecules, altering the RNA's instructions for making proteins without affecting the core DNA. Some modifications can be beneficial, as in the case of liver disease; others can have a detrimental effect.
Using a unique mouse model missing m6A RNA modifications in the liver and a control model that included the modifications, the authors compared the effects of diets with differing fat contents to assess the effects of the modifications on fatty liver disease. In addition, they used measurements from human patients who had undergone liver biopsies during bariatric surgery to correlate markers of m6A RNA modifications with liver fat content and inflammation.
A key question moving forward is how genetic and environmental factors affect the body's natural ability to create RNA modifications. Because m6A appears to act as a protective checkpoint that slows the accumulation of fat in the liver, the investigators hope their findings will spur future research on the development of therapies to enhance chemical modifications as a way to protect against liver disease and similar disorders.
The study was led by Dr. Tamer Sallam, an associate professor of medicine at the David Geffen School of Medicine at UCLA. Other authors included David Salisbury, Zhengyi Zhang, Dan Wang, Jason Kim, Xiaohui Wu, Laurent Vergnes, Kevin Williams, Adriana Huertas-Vazquez and Karen Reue, all of UCLA; David Casero of Cedars-Sinai; Aashiq Mirza and Dr. Samie Jaffrey of Cornell University; Paola Leon-Mimila of the National Autonomous University of Mexico (UNAM); and Jianjun Chen of the City of Hope Medical Institute.
The study is published today in the journal Nature Metabolism.
Funding for the study was provided by grants from the National Institutes of Health, an American Heart Association Transformational Project grant and a Burroughs Wellcome Fund Career Award for Medical Scientists.